Johnson & Johnson (NYSE:JNJ)
| CAPS Rating |
|
|---|---|
| Open | $65.46 |
| Previous Close | $65.64 |
| Daily Range | $65.05 - $65.58 |
| 52-Week Range | $57.50 - $68.05 |
| Market Cap | $178.64B |
| P/E Ratio | 15.40 |
| Dividend (Yield) | 2.28 (3.10%) |
| Volume | 9,507,100 |
| Average Daily Volume | 0 |
JNJ
VS S&P 500 (SPY)
How do you think JNJ will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
JNJ Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
JNJ News and Commentary
- Two Comeback Corporate Bonds – Minyanville
- Dr. Reddy's Going Strong - Analyst Blog – NASDAQ
- The Zacks Analyst Blog Highlights: Alkermes plc, Elan, Johnson & Johnson, Amylin Pharmaceuticals and – NASDAQ
- Allergan Terminates Sales of Lap-Band – Blogs @ The Motley Fool
- Earnings Scorecard: Johnson & Johnson - Analyst Blog – NASDAQ
- Curing Diseases Makes For a Bad Business Model – The Motley Fool
- The 3 Best Moves You Can Make With Your Money – The Motley Fool
- Venezuela's Business Sector Awaits Word On New Price Caps – SmartMoney
- This Just In: Upgrades and Downgrades – The Motley Fool
- New Growth Prospects In This Essential Industry – The Motley Fool
- Revenues Skyrocket at Merged Alkermes - Analyst Blog – NASDAQ
- Has Elan Become the Perfect Stock? – The Motley Fool
- Incivek Catalyst at Play for Vertex - Analyst Blog – NASDAQ
- Gilead Misses EPS Ests, Sales Up - Analyst Blog – NASDAQ
- 1 Cheap Biotech Small-Cap With Huge Potential – The Motley Fool
- Dendreon Gets a New CEO - Analyst Blog – NASDAQ
- Earnings Scorecard: Stryker - Analyst Blog – NASDAQ
- 4th UPDATE: Merck Swings To 4Q Profit; Sales Up 4% – SmartMoney
- High Yield Stocks With Ex-Dividend Date February 2012 – Blog at The Motley Fool
- 3rd UPDATE: Merck Swings To 4Q Profit; Sales Up 4% – SmartMoney
RSS Headlines
Fool UK
